KZIA · CIK 0001075880
Kazia Therapeutics Limited.
Annual figures as reported, FY2015–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
A$42K
▼ −98.2% vs FY2024
Net income
−A$20.7M
▲ +22.7% vs FY2024
Operating cash flow
−A$13.3M
▼ −38.6% vs FY2024
Diluted EPS
−A$0.04
▲ +62.8% vs FY2024
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedShare count change (split-adjusted)
+650.1%
5y
Key ratios
derived per fiscal year| Fiscal year | Net margin | ROE | ROA | Current ratio |
|---|---|---|---|---|
| FY2025 | −49290.5% | — | −341.6% | 0.35× |
| FY2024 | −1160.2% | — | −124.1% | 0.24× |
| FY2023 | — | −169.8% | −72.9% | 1.42× |
| FY2022 | — | −136.9% | −69.7% | 1.40× |
| FY2021 | −55.5% | −22.2% | −14.5% | 3.53× |
| FY2020 | — | −88.3% | −54.1% | 2.10× |
| FY2019 | — | −72.3% | −48.5% | 3.96× |
| FY2018 | −5074.8% | −31.4% | −21.4% | 2.38× |
| FY2017 | −4285.1% | −42.1% | −29.7% | 3.62× |
| FY2016 | −2993.8% | −35.8% | — | — |
| FY2015 | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | A$42K | — | — | −A$20.7M | −A$0.04 | −A$13.3M | — | A$6.1M | A$14.4M | −A$8.3M | A$4.3M | — |
| FY2024 | A$2.3M | — | — | −A$26.8M | −A$0.10 | −A$9.6M | — | A$21.6M | A$31.6M | −A$10.0M | A$1.7M | — |
| FY2023 | A$0 | — | — | −A$20.5M | −A$0.11 | −A$15.2M | — | A$28.1M | A$16.0M | A$12.1M | A$5.2M | — |
| FY2022 | A$0 | — | — | −A$25.0M | −A$0.19 | −A$22.8M | — | A$35.9M | A$17.6M | A$18.3M | A$7.4M | — |
| FY2021 | A$15.2M | — | — | −A$8.4M | −A$0.07 | −A$9.1M | — | A$58.1M | A$20.2M | A$37.9M | A$27.6M | — |
| FY2020 | — | — | — | −A$12.5M | −A$0.17 | −A$8.8M | — | A$23.1M | A$8.9M | A$14.1M | A$8.8M | — |
| FY2019 | — | — | — | −A$10.3M | −A$17.86 | −A$6.7M | — | A$21.2M | A$7.0M | A$14.2M | A$5.4M | — |
| FY2018 | A$119K | — | — | −A$6.0M | −A$12.48 | −A$8.7M | — | A$28.2M | A$8.9M | A$19.2M | A$6.0M | — |
| FY2017 | A$249K | — | — | −A$10.7M | −A$2.28 | −A$11.4M | — | A$35.9M | A$10.6M | A$25.3M | A$14.5M | — |
| FY2016 | A$406K | — | — | −A$12.2M | −A$2.82 | −A$12.0M | — | — | — | A$33.9M | A$33.5M | — |
| FY2015 | — | — | — | — | — | — | — | — | — | A$44.4M | A$44.4M | — |
Latest filings
the most recent regulatory filings4Insider ownership filing2026-06-23 ↗4Insider ownership filing2026-06-23 ↗3Insider ownership filing2026-06-15 ↗3Insider ownership filing2026-06-03 ↗424B3PROSPECTUS SUPPLEMENT2026-06-02 ↗424B3PROSPECTUS SUPPLEMENT2026-06-02 ↗424B3PROSPECTUS SUPPLEMENT2026-06-02 ↗424B3PROSPECTUS SUPPLEMENT2026-06-02 ↗6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-02 ↗SCHEDULE 13G/ASEC filing2026-05-27 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.